The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs

Thrombosis Research

Volumn 137, Issue , 2016, Pages 3-10

  Grosse, Scott D ^a   Nelson, Richard E ^b   Nyarko, Kwame A ^a   Richardson, Lisa C ^c   Raskob, Gary E ^d  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ACUTE DISEASE; ANTICOAGULANT THERAPY; BLEEDING; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DERMATITIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH STATUS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECURRENT DISEASE; REVIEW; RISK FACTOR; STASIS DERMATITIS; SUPERFICIAL VENOUS THROMBOSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; ULCER; UNITED STATES; VEIN INSUFFICIENCY; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; AGED; COMPUTER SIMULATION; COST CONTROL; COST OF ILLNESS; ECONOMIC MODEL; ECONOMICS; META ANALYSIS; MIDDLE AGED; MORTALITY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

AGED; COMPUTER SIMULATION; COST OF ILLNESS; COST SAVINGS; HEALTH CARE COSTS; HUMANS; INCIDENCE; MIDDLE AGED; MODELS, ECONOMIC; RISK FACTORS; SURVIVAL RATE; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84951993923     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.11.033     Document Type: Review

References (84)

1. D.P. Rice Cost of illness studies: what is good about them? Injury Prevention 6 2000 177 179
2. M. Gold, J. Siegel, L. Russell, and M. Weinstein Cost-effectiveness in Health and Medicine 1996 Oxford University Press New York
3. CDC Venous thromboembolism in adult hospitalizations - United States, 2007-2009 Morbidity and Mortality Weekly Report 2012 Centers for Disease Control and Prevention 401 404
4. HHS The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism 2008 Office of the Surgeon General
5. Thromboembolism: an under appreciated cause of death Lancet Haematology 2 2015 e393
6. S.D. Grosse Incidence-based cost estimates require population-based incidence data. A critique of Mahan et al Thromb. Haemost. 107 2012 192 193
7. C.E. Mahan, M.T. Holdsworth, S.M. Welch, M. Borrego, and A.C. Spyropoulos Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event Thromb. Haemost. 106 2011 405 415
8. C.E. Mahan, M.E. Borrego, A.L. Woersching, R. Federici, R. Downey, J. Tiongson, and et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates Thromb. Haemost. 108 2012 291 302
9. J.A. Heit Venous thromboembolism: disease burden, outcomes and risk factors J. Thromb. Haemost. 3 2005 1611 1617
10. W. Huang, R.J. Goldberg, F.A. Anderson, C.I. Kiefe, and F.A. Spencer Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009) Am. J. Med. 127 2014 829 839 e5
11. E. Oger Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale Thromb. Haemost. 83 2000 657 660
12. V. Tagalakis, V. Patenaude, S.R. Kahn, and S. Suissa Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study cohort The American Journal of Medicine 126 832 2013 e13 e21
13. S. Braekkan, E. Mathiesen, I. Njølstad, T. Wilsgaard, J. Størmer, and J. Hansen Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromsø study J. Thromb. Haemost. 6 2008 1851 1857
14. I. Naess, S. Christiansen, P. Romundstad, S. Cannegieter, F.R. Rosendaal, and J. Hammerstrøm Incidence and mortality of venous thrombosis: a population-based study J. Thromb. Haemost. 5 2007 692 699
15. S. Deitelzweig, B. Johnson, J. Lin, and K. Schulman Prevalence of clinical venous thromboembolism in the USA: current trends and future projections Am. J. Hematol. 86 2011 217 220
16. G.F. Riley Administrative and claims records as sources of health care cost data Med. Care 47 2009 S51 S55
17. W.E. Barlow Overview of methods to estimate the medical costs of cancer Med. Care 47 2009 S33 S36
18. J. Lipscomb, P.G. Barnett, M.L. Brown, W. Lawrence, and K.R. Yabroff Advancing the science of health care costing Med. Care 47 2009 S120 S126
19. W.E. Encinosa, and F.J. Hellinger The impact of medical errors on ninety-day costs and outcomes: an examination of surgical patients Health Serv. Res. 43 2008 2067 2085
20. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch. Intern. Med. 160 2000 809 815
21. G. Kourlaba, J. Relakis, C. Mylonas, V. Kapaki, S. Kontodimas, M.V. Holm, and et al. The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review Blood Coagul. Fibrinolysis 26 2015 13 31
22. C.K. Boscardin, R. Gonzales, K.L. Bradley, and M.C. Raven Predicting cost of care using self-reported health status data BMC Health Serv. Res. 15 2015 406
23. Bureau of Economic Analysis (BEA) What Accounts for the Differences in the PCE Price Index and the Consumer Price Index? (Washington, D.C.) 2010
24. D.A. MacDougall, A.L. Feliu, S.J. Boccuzzi, and J. Lin Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome Am. J. Health Syst. Pharm. 63 2006 S5 S15
25. A. Ruppert, T. Steinle, and M. Lees Economic burden of venous thromboembolism: a systematic review J. Med. Econ. 14 2011 65 74
26. P. Lefebvre, F. Laliberte, E.A. Nutescu, M.S. Duh, J. LaMori, B.K. Bookhart, and et al. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries J. Manag. Care Pharm. 18 2012 363 374
27. C. Kearon, and E.A. Akl Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism Blood 123 2014 1794 1801
28. P. Diehr, D. Yanez, A. Ash, M. Hornbrook, and D. Lin Methods for analyzing health care utilization and costs Annu. Rev. Public Health 20 1999 125 144
29. A. Spyropoulos, and J. Lin Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations J. Manag. Care Pharm. 13 2007 475
30. Y. Huang Cost analysis with censored data Med. Care 47 2009 S115 S119
31. P.A. Kyrle, F.R. Rosendaal, and S. Eichinger Risk assessment for recurrent venous thrombosis Lancet 376 2010 2032 2039
32. T. Baglin, R. Luddington, K. Brown, and C. Baglin Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study Lancet 362 2003 523 526
33. P. Lefebvre, F. Laliberté, E.A. Nutescu, M.S. Duh, J. LaMori, B.K. Bookhart, and et al. All-cause and disease-related health care costs associated with recurrent venous thromboembolism Thromb. Haemost. 110 2013 1288 1297
34. D. Bergqvist, S. Jendteg, L. Johansen, U. Persson, and K. Odegaard Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden Ann. Intern. Med. 126 1997 454 457
35. S.R. Kahn, I. Shrier, J.A. Julian, T. Ducruet, L. Arsenault, M.-J. Miron, and et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis Ann. Intern. Med. 149 2008 698 707
36. S.R. Kahn, S. Shapiro, P.S. Wells, M.A. Rodger, M.J. Kovacs, D.R. Anderson, and et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial Lancet 383 2014 880 888
37. S. Schulman, P. Lindmarker, M. Holmström, G. Lärfars, A. Carlsson, P. Nicol, and et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months J. Thromb. Haemost. 4 2006 734 742
38. D.N. Mohr, M.D. Silverstein, J.A. Heit, T.M. Petterson, W.M. O'fallon, and L.J. Melton The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study Mayo Clinic Proceedings 2000 Elsevier 1249 1256
39. A.A. Ashrani, and J.A. Heit Incidence and cost burden of post-thrombotic syndrome J. Thromb. Thrombolysis 28 2009 465 476
40. P. Prandoni, and S.R. Kahn Post-thrombotic syndrome: prevalence, prognostication and need for progress Br. J. Haematol. 145 2009 286 295
41. R. Kreidy Contribution of recurrent venous thrombosis and inherited thrombophilia to the pathogenesis of postthrombotic syndrome Clin. Appl. Thromb. Hemost. 21 2015 87 90
42. R. Guanella, T. Ducruet, M. Johri, M.J. MIRON, A. Roussin, S. Desmarais, and et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation J. Thromb. Haemost. 9 2011 2397 2405
43. J.A. Caprini, M.F. Botteman, J.M. Stephens, V. Nadipelli, M.M. Ewing, S. Brandt, and et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States Value Health 6 2003 59 74
44. R. Copher, A. Cerulli, A. Watkins, and M.M. Laura Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States J. Med. Econ. 15 2012 947 955
45. S. Johnson, T. Delate, A. Boka, P. Shaw, and C. Zager Characterizing the financial burden of pulmonary arterial hypertension within an integrated healthcare delivery system J. Med. Econ. 16 2013 1414 1422
46. S. Ozsu, and H. Cinarka Chronic thromboembolic pulmonary hypertension: medical treatment Pulmonary Circulation 3 2013 341
47. F.A. Klok, K.W. van Kralingen, A.P. van Dijk, F.H. Heyning, H.W. Vliegen, and M.V. Huisman Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism Haematologica 95 2010 970 975
48. C. Becattini, G. Agnelli, R. Pesavento, M. Silingardi, R. Poggio, M.R. Taliani, and et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism Chest 130 2006 172 175
49. D. Poli, and M. Miniati The incidence of recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension following a first episode of pulmonary embolism Current Opinion in Pulmonary Medicine 17 2011 392 397
50. R. Otero, M. Oribe, A. Ballaz, D. Jimenez, F. Uresandi, D. Nauffal, and et al. Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism Thromb. Res. 127 2011 303 308
51. M. Miniati, S. Monti, M. Bottai, E. Scoscia, C. Bauleo, L. Tonelli, and et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism Medicine 85 2006 253 262
52. V. Pengo, A.W. Lensing, M.H. Prins, A. Marchiori, B.L. Davidson, F. Tiozzo, and et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism N. Engl. J. Med. 350 2004 2257 2264
53. F. Dentali, M. Donadini, M. Gianni, A. Bertolini, A. Squizzato, A. Venco, and et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism Thromb. Res. 124 2009 256 258
54. N.Y. Kirson, H.G. Birnbaum, J.I. Ivanova, T. Waldman, V. Joish, and T. Williamson Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population Applied Health Economics and Health Policy 9 2011 377 387
55. A. Barros, R. Baptista, A. Nogueira, E. Jorge, R. Teixeira, G. Castro, and et al. Predictors of pulmonary hypertension after intermediate-to-high risk pulmonary embolism Revista Portuguesa de Cardiologia (English Edition) 32 2013 857 864
56. P. Lefebvre, C. Coleman, B. Bookhart, S. Wang, S. Mody, K. Tran, and et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism J. Med. Econ. 17 2014 52
57. J.A. O'Brien, and J.J. Caro Direct medical cost of managing deep vein thrombosis according to the occurrence of complications PharmacoEconomics 20 2002 603 615
58. M.F. Bullano, V. Willey, O. Hauch, G. Wygant, A.C. Spyropoulos, and L. Hoffman Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization J. Manag. Care Pharm. 11 2005 663 673
59. L.J. McGarry, D. Thompson, M.C. Weinstein, and S.Z. Goldhaber Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients Am. J. Manag. Care 10 2004 632 642
60. Bureau of Labor Statistics (BLS). The Consumer Price Index (updated 6/2015). Washington, D.C., 2015.
61. A.C. Spyropoulos, J.S. Hurley, G.N. Ciesla, and G. de Lissovoy Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin Chest 122 2002 108 114
62. F.M. Creekmore, G.M. Oderda, R.C. Pendleton, and D.I. Brixner Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism Pharmacotherapy 26 2006 1438 1445
63. H.M. Kaafarani, A.M. Borzecki, K.M. Itani, S. Loveland, H.J. Mull, K. Hickson, and et al. Validity of selected patient safety indicators: opportunities and concerns J. Am. Coll. Surg. 212 2011 924 934
64. R.E. Nelson, S.D. Grosse, N.J. Waitzman, J. Lin, S.L. DuVall, O. Patterson, and et al. Using multiple sources of data for surveillance of postoperative venous thromboembolism among surgical patients treated in Department of Veterans Affairs hospitals, 2005-2010 Thromb. Res. 135 2015 636 642
65. A.G. Holst, G. Jensen, and E. Prescott Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study Circulation 121 2010 1896 1903
66. J.A. Heit Epidemiology of venous thromboembolism Nat. Rev. Cardiol. 12 2015 464 474
67. ISTH Steering Committee for World Thrombosis Day Thrombosis: a major contributor to the global disease burden J. Thromb. Haemost. 12 2014 1580 1590
68. A.M. Wendelboe, J. Campbell, M. McCumber, D. Bratzler, K. Ding, M. Beckman, and et al. The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods Am. Heart J. 170 2015 447 454 e18
69. M.A. Rogers, D.A. Levine, N. Blumberg, S.A. Flanders, V. Chopra, and K.M. Langa Triggers of hospitalization for venous thromboembolism Circulation 125 2012 2092 2099
70. R.H. White Identifying risk factors for venous thromboembolism Circulation 125 2012 2051 2053
71. K.R. Yabroff, J.L. Warren, D. Schrag, A. Mariotto, A. Meekins, M. Topor, and et al. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients Med. Care 47 2009 S56 S63
72. S.Z. Goldhaber, L. Visani, and M. De Rosa Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Lancet 353 1999 1386 1389
73. V. McLaughlin, S. Archer, and D. Badesch A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension Circulation 119 2009 2250 2294
74. L. Christensen, R. Sasane, P. Hodgkins, C. Harley, and S. Tetali Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population Curr. Med. Res. Opin. 26 2010 977 989
75. A. Amin, A. Bruno, J. Trocio, J. Lin, and M. Lingohr-Smith Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism versus warfarin or placebo in the US J. Med. Econ. 1-34 2015
76. O. Baser, D. Supina, N. Sengupta, L. Wang, and L. Kwong Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery Am. J. Health Syst. Pharm. 67 2010 1438 1445
77. S.L. Boulet, D. Amendah, S.D. Grosse, and W.C. Hooper Health care expenditures associated with venous thromboembolism among children Thromb. Res. 129 2012 583 587
78. E.A. Nutescu, A.F. Shorr, E. Farrelly, H. Ruslan, L.E. Happe, and M. Franklin Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery Ann. Pharmacother. 42 2008 1216 1221
79. F. Vekeman, J.C. LaMori, F. Laliberté, E. Nutescu, M.S. Duh, B.K. Bookhart, and et al. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population J. Med. Econ. 14 2011 324 334
80. G. Connolly, M. Dalal, J. Lin, and A. Khorana Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer Lung Cancer 78 2012 253 258
81. A.A. Khorana, M.R. Dalal, J. Lin, and G.C. Connolly Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States ClinicoEconomics and Outcomes Research 5 2013 101
82. G.H. Lyman, L. Eckert, Y. Wang, H. Wang, and A. Cohen Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis Oncologist 18 2013 1321 1329
83. T. Wun, and R.H. White Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors Cancer Invest. 27 2009 63 74
84. M.L. Louzada, H. Majeed, V. Dao, and P.S. Wells Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies Blood Coagul. Fibrinolysis 22 2011 86 91